HDAC9 and mantle cell lymphoma: Such data confirm the real survival benefit promoted by up-front consolidation with ASCT in young and physically fit patients with MCL considered eligible for this therapeutic strategy, regardless of whether the induction regimen is based on the use of HDAC.